

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

9

of

15

Complete if Known

Application Number	10/803,580
Filing Date	March 17, 2004
First Named Inventor	Jerome C. Bressi
Group Art Unit	1625
Examiner Name	Celia C. Chang
Attorney Docket Number	HDAC-5005-C2

CC	KS	WO 00/021979 A2 & A3	4/20/2000	FUJISAWA PHARMACEUTICAL CO., LTD.		
	KT	WO 00/023567 A2 & A3	4/27/2000	NOVARTIS AG		
	KU	WO 00/52033 A1	9/8/2000	JAPAN ENERGY CORPORATION		
	KV	WO 00/56917 A1	9/28/2000	CHUGAI RESEARCH INSTITUTE FOR MOLECULAR MEDICINE, INC.		
	KW	WO 00/418045 A1 WO 00/18045 A1 03/15/2001	10/8/2000	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	KX	WO 00/61576 A1	10/19/2000	SMITHKLINE BEECHAM CORPORATION		
	KY	WO 00/71703 A2 & A3	11/30/2000	METHYLGENE INC.		
	KZ	WO 01/07042 A1	2/1/2001	MERCK & CO., INC.		
	LA	WO 01/14581 A3	3/1/2001	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM		
	LB	WO 01/16106 A1	3/8/2001	SCHERING AKTIENGESELLSCHAFT		
	LC	WO 01/17514 A1	3/15/2001	SALK INSTITUTE OF BIOLOGICAL STUDIES		
	LD	WO 01/018045 A1	3/15/2001	TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK		
	LE	WO 01/18171 A2 & A3	3/15/2001	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	LF	WO 01/27314 A1	4/19/2001	MERCK & CO., INC.		
	LG	WO 01/38322 A1	5/31/2001	METHYLGENE, INC.		
	LH	WO 01/42437 A2 & A3	6/14/2001	AXYS PHARMACEUTICALS, INC.		
	LI	WO 01/67107 A1	9/13/2001	IMPERIAL COLLEGE INNOVATIONS LIMITED		
	LJ	WO 01/70675 A3	9/27/2001	METHYLGENE, INC.		
	LK	WO 01/72784 A2 & A3	10/4/2001	FILGEN BIOSCIENCES, INC.		
	LL	WO 01/72737 A1	10/4/2001	SMITHKLINE BEECHAM CORPORATION		
	LM	WO 02/06307 A1	1/24/2002	FUJISAWA PHARMACEUTICAL CO., LTD.		
	LN	WO 02/08273 A2 & A3	1/31/2002	MILLENNIUM PHARMACEUTICALS, INC.		
	LO	WO 02/07722 A2 & A3	1/31/2002	GEORG-SPEYER-HAUS		
	LP	WO 02/15921 A2 & A3	2/28/2002	GOVERNMENT OF UNITED STATES OF AMERICA, represented by SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
	LQ	WO 02/22133 A1	3/21/2002	VIRGINIA COMMONWEALTH UNIVERSITY		
	LR	WO 02/22577 A3	3/21/2002	NOVARTIS AG		
CC	LS	WO 02/26896 A1	4/4/2002	PROLIFIX LIMITED		

Examiner
Signature

/Celia Chang/

Date
Considered

08/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.